Mice lacking caspase-2 are protected from behavioral changes, but not pathology, in the YAC128 model of Huntington disease
Authors:
- Jeffrey B CarrollJCJeffrey B Carroll
- Amber L SouthwellASAmber L Southwell
- Rona K GrahamRGRona K Graham
- Jason P LerchJLJason P Lerch
- Dagmar E EhrnhoeferDEDagmar E Ehrnhoefer
- Li-Ping CaoLCLi-Ping Cao
- Wei-Ning ZhangWZWei-Ning Zhang
- Yu DengYDYu Deng
- Nagat BissadaNBNagat Bissada
- R Mark HenkelmanRHR Mark Henkelman
- Michael R HaydenMHMichael R Hayden
Open Access
- 19 August 2011
- journal article
- Published by Springer Nature in Molecular Neurodegeneration
- Vol. 6 (1) , 59
Abstract
Background: Huntington Disease (HD) is a neurodegenerative disorder in which caspase activation and cleavage of substrates, including the huntingtin protein, has been invoked as a pathological mechanism. Specific changes in caspase-2 (casp2) activity have been suggested to contribute to the pathogenesis of HD, however unique casp2 cleavage substrates have remained elusive. We thus utilized mice completely lacking casp2 (casp2-/-) to examine the role played by casp2 in the progression of HD. This 'substrate agnostic' approach allows us to query the effect of casp2 on HD progression without pre-defining proteolytic substrates of interest. Results: YAC128 HD model mice lacking casp2 show protection from well-validated motor and cognitive features of HD, including performance on rotarod, swimming T-maze, pre-pulse inhibition, spontaneous alternation and locomotor tasks. However, the specific pathological features of the YAC128 mice including striatal volume loss and testicular degeneration are unaltered in mice lacking casp2. The application of high-resolution magnetic resonance imaging (MRI) techniques validates specific neuropathology in the YAC128 mice that is not altered by ablation of casp2. Conclusions: The rescue of behavioral phenotypes in the absence of pathological improvement suggests that different pathways may be operative in the dysfunction of neural circuitry in HD leading to behavioral changes compared to the processes leading to cell death and volume loss. Inhibition of caspase-2 activity may be associated with symptomatic improvement in HD.Keywords
This publication has 60 references indexed in Scilit:
- Intrabody Gene Therapy Ameliorates Motor, Cognitive, and Neuropathological Symptoms in Multiple Mouse Models of Huntington's DiseaseJournal of Neuroscience, 2009
- Cortical thickness measured from MRI in the YAC128 mouse model of Huntington's diseaseNeuroImage, 2008
- No death without life: vital functions of apoptotic effectorsCell Death & Differentiation, 2008
- Reversal of Alzheimer's-like pathology and behavior in human APP transgenic mice by mutation of Asp664Proceedings of the National Academy of Sciences, 2006
- Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington diseaseExperimental Neurology, 2005
- Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's diseaseCell Death & Differentiation, 2004
- Task-Set Switching Deficits in Early-Stage Huntington's Disease: Implications for Basal Ganglia FunctionJournal of Cognitive Neuroscience, 2003
- Multiple caspases are involved in β‐amyloid‐induced neuronal apoptosisJournal of Neuroscience Research, 2001
- Inhibiting Caspase Cleavage of Huntingtin Reduces Toxicity and Aggregate Formation in Neuronal and Nonneuronal CellsJournal of Biological Chemistry, 2000
- Executive and mnemonic functions in early Huntington's diseaseBrain, 1996